



Dr. **Dionyssios Sgouras** is currently *Research Director* of the Laboratory of Medical Microbiology of the Hellenic Pasteur Institute. Since May 2014, he has also been appointed as *Head of the Vaccine Unit* at Hellenic Pasteur Institute, following the approval of the National Organization for Medicines. Since 2016 he is serving as *General Secretary* of the Hellenic Society of Biochemistry & Molecular Biology, a FEBS constituent society.

Present research interests focus on bacterial pathogenesis and most specifically, *Helicobacter pylori* virulence factors and their effect on host intracellular signaling pathways, focusing mainly on epithelial cell pathogenesis and tissue remodeling during the infection. To this end, he participated in FP5 program PRO-PATH CT-2000-01179 “Molecular Analysis and Mechanistic Elucidation of the Functionality of Probiotics and Prebiotics in the Inhibition of Pathogenic Microorganisms to Combat Gastrointestinal Disorders and to Improve Human Health” and as an external contractor in the FP6 program ANR-06-PATHO-00701 project ERA-NET “Parasite and host genetic diversity in *Helicobacter* infections.” He was also involved in FP7 INFRA-2010-2.2.8 project ERINHA “European Research Infrastructure on Highly Pathogenic Agents” and later of H2020-INFRADEV-1-2015-2 project ERINHA2 (689622) with regards to the construction and implementation of a pan-European high security BSL-4 research infrastructure for research on suspected group-4 pathogens. This particular project supported the development of standard operating procedures and conditions for the detection and typing of infectious agents in human and veterinary samples, for the Diagnostic Department and the WHO-accredited National Reference Laboratories of the Hellenic Pasteur Institute.

With regards to the Vaccines Unit of Hellenic Pasteur Institute he is responsible for the structural and operational upgrade to current GMP guidelines with the aim to its subsequent evolution into a Model Pharmaceutical Unit for small-scale, productions of sterile parenteral solutions for human and veterinary use. The development and operation of such a modern infrastructure, compliant with current EU GMP regulations, aims to support also small-scale production needs for Research and Development into new therapeutic agents and preventive vaccination approaches. To this end he successfully prepared the investment proposal to I.S. Niarchos for the 810,000 € donation destined exclusively for the HPI vaccine unit Structural Renovation, as a part of the co-ordination team.

Education and previous Positions

- 1985 B.Sc. (Chemistry) with honors (8/10) from the **National & Kapodistrian University of Athens**
- 1987 M.Sc. (by research) at the **Department of Postgraduate Medicine of the University of Keele, UK**, on the evaluation of biocompatibility of a novel organosilicate polymer for biomedical use.
- 1990 PhD **Cancer Research Campaign’s Polymer-Controlled Drug Delivery Research Group, University of Keele, UK**, on the biological characterization of soluble synthetic polymers to be used as carriers for controlled drug delivery of anticancer anthracycline antibiotics.
- 1991 Postdoctoral Research Fellow at the **Cancer Research Campaign’s Polymer-Controlled Drug Delivery Research Group, University of Keele, UK**, working on the development of anticancer drug formulations for first order targeting to the lung, a project supported by Farmitalia Carlo Erba (Italy).
- 1992-1995 Postdoctoral Research Fellow, **U.S. National Institutes of Health-Fogarty International Fellowship, Laboratory of Molecular Oncology, National Cancer Institute, National Institutes of Health**, Frederick Cancer Research and Development Center, Frederick, MD. Isolation and molecular characterization of *ERF*, a transcription factor of the *ETS* family of human oncogenes.
- 1996-1997 **Hellenic Armed Forces** conscription, Hellenic Airforce, 251th Airforce Hospital, Department of Nuclear Medicine and the Biochemistry Department.
- 1997-2002 Staff Scientist **Diagnostic Genetic Center S.A.**, a private laboratory involved in cytogenetic, biochemical and molecular prenatal screening.
- 1999-2002 Postdoctoral Research Fellow, **Hellenic Pasteur Institute**, Laboratory of Medical Microbiology
- May 2002 elected *Assistant Researcher*, **Hellenic Pasteur Institute**, Laboratory of Medical Microbiology
- April 2010 promoted to *Principal Investigator*, **Hellenic Pasteur Institute**, Laboratory of Medical Microbiology
- January 2018 promoted to the position of *Research Director*, **Hellenic Pasteur Institute**, Lab of Medical Microbiology

He has co-authored over 170 publications including 40 publications in peer reviewed international journals, 3 publications in national journals, one invited book chapter, over 60 papers in international conferences and 70 papers in national conferences. He holds 2 patents (US 6194547 and US 5856125) and has given over 20 invited talks in international conferences.

Research Funding

- Member of the co-ordination team for the investment proposal to I.S. Niarchos “DEVELOPMENT OF INNOVATIVE BIOLOGICAL PRODUCTS AND SERVICES FOR INFECTIOUS AND NEURODEGENERATIVE DISEASES. Responsible for the HPI vaccine unit Renovation program. 810,000 €
- H2020-INFRADEV-1-2015-2 project ERINHA2 (689622) “European Research Infrastructure on Highly Pathogenic Agents” European Commission, 45,187 €
- Member of co-ordination team in InfeNeuTra-2012 (MIS-450598) “Infectious and neurodegenerative diseases in the 21st Century: Basic Mechanisms to translational research for diagnosis, prevention and therapy”, GSRT 1,500,000 €
- Hellenic Society of Gastrointestinal Oncology and Experimental Research Center–ELPEN Grant 20,000 €

- FP7 INFRA-2010-2.2.8 project ERINHA “European Research Infrastructure on Highly Pathogenic Agents” European Commission, 61,026 €
- ERA-NET ANR-06-PATHO-00701 “Parasite and host genetic diversity in *Helicobacter* infections”, 2007-10, European Union 14,656 €
- Actions Concertées Inter Pasteuriennes-ACIP 92-19-01 “Etude de la fréquence de l'infection par *Helicobacter pylori*(Hp) des patients présentant une pathologie gastro-duodénale, de la sensibilité des souches aux antibiotiques et de la diversité de la région 3' du gène cagA”, 2007-08, Institut Pasteur Paris, 8,214 €
- HPI-922616 “CagA motogenic effects induced on gastric epithelial cells upon *H. pylori* infection in vitro. Study on the interaction of CagA with PLC and effect on intracellular Ca²⁺ levels”, 2004-07, Hellenic Pasteur Institute, 13,500 €
- PROPATH CT-2000-01179 “Molecular Analysis and Mechanistic Elucidation of the Functionality of Probiotics and Prebiotics in the Inhibition of Pathogenic Microorganisms to Combat Gastrointestinal Disorders and to Improve Human Health”, 2002-2005, European Union, 247,247 €

Selected Publications

- Georgopoulos SD, Papastergiou V, Martinez-Gonzalez B, Xirouchakis E, Familias I, Sgouras D, Mentis A, Karatapanis S. Hybrid therapy as first-line regimen for *Helicobacter pylori* eradication in a high clarithromycin resistance area: a prospective open-label trial. *Ann Gastroenterol*. 2018 Mar-Apr;31(2):205-210. doi: 10.20524/aog.2017.0221. Epub 2017 Dec 15.
- Bugaytsova J, Chernov YA, Gideonsson P, Henriksson S, Mendez M, Sjöström R, Mahdavi J, Shevtsova A, Quintana-Hayashi M, Ilver D, Moskalenko R, Aisenbrey C, Bylund G, Schmidt A, Moonens K, Björnham O, Brännström K, Königer V, Vikström S, Rakhimova L, Ögren L, Hofer A, Liu H, Goldman M, Whitmire JM, Younson JS, Kelly CG, Gilman RH, Chowdhury A, Mukhopadhyay AK, Nair BG, Papadakos KS, Martínez-Gonzalez B, Sgouras DN, Engstrand L, Unemo M, Danielsson D, Suerbaum S, Oscarson S, Morozova-Roche L, Gröbner G, Holgersson J, Esberg A, Strömberg N, Eldridge A, Chromy BA, Hansen LM, Solnick JV, Schedin S, Lindén SK, Haas R, Dubois A, Merrell DS, Remaut H, Arnqvist A, Berg DE, Borén T. (2016) Adaptation of the oncopathogen *H. pylori* during chronic infection and to gastric disease by acid responsive adherence *Cell Host & Microbe* (2017) Mar 8;21(3):376-389, doi: 10.1016/j.chom.2017.02.013
- Georgopoulos SD, Xirouchakis E, Martinez-Gonzales B, Zampeli E, Grivas E, Spiliadi C, Sotiropoulou M, Petraki K, Zografos K, Laoudi F, Sgouras D, Mentis A, Kasapidis P, Michopoulos S. (2016) Randomized clinical trial comparing ten day concomitant and sequential therapies for *Helicobacter pylori* eradication in a high clarithromycin resistance area. *Eur J Intern Med*. pii: S0953-6205(16)30080-2. doi: 10.1016/j.ejim.2016.04.011.
- Costa AM, RM Ferreira, I Pinto-Ribeiro, IS Sougleri, MJ Oliveira, L Carreto, MA Santos, DN Sgouras, F Carneiro, M Leite and C Figueiredo (2016) *Helicobacter pylori* activates matrix metalloproteinase-10 in gastric epithelial cells via EGFR and ERK-mediated pathways. *J Infect Dis*. 213(11): 1767-76 doi: 10.1093/infdis/jiw031
- Sougleri IS, KS Papadakos, MP Zadik, M Mavri-Vavagianni, AF Mentis and DN Sgouras (2015) *Helicobacter pylori* CagA protein induces factors involved in the Epithelial-to-Mesenchymal-Transition (EMT) in infected gastric epithelial cells in an EPIYA- phosphorylation-dependent manner. *FEBS J*. doi: 10.1111/febs.13592
- Sgouras DN, Trang TT, Yamaoka Y. (2015) Pathogenesis of *Helicobacter pylori* Infection. *Helicobacter*. Sep;20 Suppl 1:8-16. doi: 10.1111/hel.12251.
- Pogka V, Moutousi A, Kossyvakis A, Kalliaropoulos A, Sgouras DN, Giannaki M, Mentis AF. (2014) Genetic variability of human metapneumo- and bocaviruses in children with respiratory tract infections. *Influenza Other Respir Viruses*. Jan; 8(1):107-15
- Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, and Laoudi F. (2013) Clinical evaluation of a ten day regimen with Esomeprazole, Metronidazole, Amoxicillin, and Clarithromycin for the eradication of *Helicobacter pylori* in a high Clarithromycin resistance area. *Helicobacter*. 2013 Dec; 18(6):459-67.
- Papadakos KS, Sougleri IS, Mentis AF, Hatziloukas E, Sgouras DN. (2013) Presence of Terminal EPIYA Phosphorylation Motifs in *Helicobacter pylori* CagA Contributes to IL-8 Secretion, Irrespective of the Number of Repeats. *PLoS One* 8:e56291.
- Papadakos KS, Sougleri IS, Mentis AF, Sgouras DN. (2013) A Mutagenesis Method for the Addition and Deletion of Highly Repetitive DNA Regions: The Paradigm of EPIYA Motifs in the cagA Gene of *Helicobacter pylori*. *Helicobacter*; 18(3):229-41.
- Mueller D, Tegtmeyer N, Brandt S, Yamaoka Y, De Poire E, Sgouras D, Wessler S, Torres J, Smolka A, Backert S. (2012) c-Src and c-Abl kinases control hierarchic phosphorylation and function of the CagA effector protein in Western and East Asian *Helicobacter pylori* strains. *Journal of Clinical Investigation* 122:1553-1566.
- Altman E, Chandan V, Harrison BA, Panayotopoulou EG, Roma-Giannikou E, Li J, Sgouras DN. (2012) *Helicobacter pylori* isolates from Greek children express type 2 and type 1 Lewis and alpha 1,6-glucan antigens in conjunction with a functional type IV secretion system. *Journal of Medical Microbiology* 61:559- 566.
- Boziki M, Grigoriadis N, Deretzi G, Lagoudaki R, Panayotopoulou E, Sgouras D, Mentis A, Tascos N, Kountouras J. (2012) *Helicobacter pylori* Immunomodulative Properties in a Mouse Model of Multiple Sclerosis. *Immunogastroenterology* 1: 34-39
- Pogka V, Kossivakis A, Kalliaropoulos A, Moutousi A, Sgouras D, Panagiotopoulos T, Chrousos GP, Theodoridou M, Syriopoulou VP, Mentis AF. (2011) Respiratory Viruses Involved in Influenza-Like Illness in a Greek Pediatric Population During the Winter Period of the Years 2005-2008. *Journal of Medical Virology* 83:1841-1848.

- Melidou A, Gioula G, Pogka V, Exindari M, Moutoussi A, Sgouras D, Papadakos K, Chatzidimitriou D, Karabaxoglou D, Mentis A, Malisiovas N. (2011) Molecular and phylogenetic analysis of Greek measles 2010 strains. *Epidemiology and Infection* 140:432-438.
- Breurec S, Michel R, Seck A, Brisse S, Come D, Dieye FB, Garin B, Huerre M, Mbengue M, Fall C, Sgouras DN, Thiberge JM, Dia D, Raymond J. (2011) Clinical relevance of cagA and vacA gene polymorphisms in *Helicobacter pylori* isolates from Senegalese patients. *Clinical Microbiology and Infection* 18:153-159.
- Breurec S, Guillard B, Hem S, Papadakos KS, Brisse S, Huerre M, Monchy D, Oung C, Sgouras DN, Tan TS, Thiberge J-M, Vong S, Raymond J, Linz B. (2011) Expansion of European vacA and cagA alleles to East-Asian *Helicobacter pylori* strains in Cambodia. *Infection Genetics and Evolution* 11:1899-1905.
- Roma-Giannikou E, Roubani A, Sgouras DN, Panayiotou J, van-Vliet C, Polyzos A, Roka K, Daikos G. (2010) Endoscopic Tests for the Diagnosis of *Helicobacter pylori* Infection in Children: Validation of Rapid Urease Test. *Helicobacter* 15:227-232.
- Panayotopoulou EG, Sgouras DN, Papadakos KS, Petraki K, Breurec S, Michopoulos S, Mantzaris G, Papatheodoridis G, Mentis A, Archimandritis A. (2010) CagA and VacA Polymorphisms Are Associated with Distinct Pathological Features in *Helicobacter pylori*-Infected Adults with Peptic Ulcer and Non-Peptic Ulcer Disease. *Journal of Clinical Microbiology* 48:2237-2239.
- Sgouras DN, Panayotopoulou EG, Papadakos K, Martinez-Gonzalez B, Roumbani A, Panayiotou J, vanVliet-Constantinidou C, Mentis AF, Roma-Giannikou E. (2009) CagA and VacA Polymorphisms Do Not Correlate with Severity of Histopathological Lesions in *Helicobacter pylori*-Infected Greek Children. *Journal of Clinical Microbiology* 47:2426-2434.
- Maragkoudakis PA, Papadelli M, Georgalaki M, Panayotopoulou EG, Martinez-Gonzalez B, Mentis AF, Petraki K, Sgouras DN, Tsakalidou E. (2009) In vitro and in vivo safety evaluation of the bacteriocin producer *Streptococcus macedonicus* ACA-DC 198. *International Journal of Food Microbiology* 133:141-147.
- Logotheti M, Pogka V, Horefti E, Papadakos K, Giannaki M, Pangalis A, Sgouras D, Mentis A. (2009) Laboratory investigation and phylogenetic analysis of enteroviruses involved in an aseptic meningitis outbreak in Greece during the summer of 2007. *Journal of Clinical Virology* 46:270-274.
- Logotheti M, Kokotas S, Horefti E, Giannaki M, Pagali A, Poga V, Papadakos K, Kansouzidou A, Spala G, Panayiotopoulos T, Georgakopoulou T, Sgouras D, Mentis A. (2009) Laboratory investigation of a measles outbreak in Greece, 2005-2006. *Archives of Hellenic Medicine* 26:90-97.
- Alam MZ, Haralambous C, Kuhls K, Gouzou E, Sgouras D, Soteriadou K, Schnur L, Pralong F, Schoenian G. (2009) The paraphyletic composition of *Leishmania donovani* zymodeme MON-37 revealed by multilocus microsatellite typing. *Microbes and Infection* 11:707-715.
- Kokotas SN, Bolanaki E, Sgouras D, Pogka V, Logotheti M, Kossivakis A, Horefti E, Papadakos K, Mentis A. (2008) Cocirculation of genotypes D4 and D6 in Greece during the 2005 to 2006 measles epidemic. *Diagnostic Microbiology and Infectious Disease* 62:58-66.
- Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A, Maragkoudakis P, Mentis A, Sgouras D, Skaltsounis A-L. (2007) In vitro and in vivo activities of chios mastic gum extracts and constituents against *Helicobacter pylori*. *Antimicrobial Agents and Chemotherapy* 51:551-559.
- Panayotopoulou EG, Sgouras DN, Papadakos K, Kalliaropoulos A, Papatheodoridis G, Mentis AF, Archimandritis AJ. (2007) Strategy to characterize the number and type of repeating EPIYA phosphorylation motifs in the carboxyl terminus of CagA protein in *Helicobacter pylori* clinical isolates. *Journal of Clinical Microbiology* 45:488-495.
- Sgouras DN, Panayotopoulou EG, Martinez-Gonzalez B, Petraki K, Michopoulos S, Mentis A. (2005) *Lactobacillus johnsonii* La1 attenuates *Helicobacter pylori*-associated gastritis and reduces levels of proinflammatory chemokines in C57BL/6 mice. *Clinical and Diagnostic Laboratory Immunology* 12:1378-1386.
- Sgouras D, Maragkoudakis P, Petraki K, Martinez-Gonzalez B, Eriotou E, Michopoulos S, Kalantzopoulos G, Tsakalidou E, Mentis A. (2004) In vitro and in vivo inhibition of *Helicobacter pylori* by *Lactobacillus casei* strain Shirota. *Applied and Environmental Microbiology* 70:518-526.
- De Vuyst L, Makras L, Avonts L, Holo H, Yi Q, Servin A, Fayol-Messaoudi D, Berger C, Zoumpopoulou G, Tsakalidou E, Sgouras D, Martinez-Gonzales B, Panayotopoulou E, Mentis A, Smarandache D, Savu L, Thonart P, Nes I. (2004) Antimicrobial potential of probiotic or potentially probiotic lactic acid bacteria, the first results of the International European Research Project PROPATH of the PROEUHEALTH cluster. *Microbial Ecology in Health and Disease* 16:125-130.
- Sgouras D, Maragkoudakis P, Petraki K, Martinez B, Michopoulos S, Tsakalidou E, Kalantzopoulos G, Mentis A. (2002) Inhibition of *H. pylori* colonization and associated gastritis in the HpSS1 C57BL/6 mouse model via administration of the probiotic *Lactobacillus paracasei* subsp. *paracasei* ACA-DC 6002. *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*:60.
- Maragoudakis PA, Miaris C, Sgouras D, Mentis A, Kalantzopoulos G, Tsakalidou E. (2002) In vitro evaluation of the probiotic potential of *Lactobacillus* strains and their application in yoghurt. *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*:51.
- Le Gallic L, Sgouras D, Beal Jr G, Mavrothalassitis G. (1999) Transcriptional repressor ERF is a Ras/mitogenactivated protein kinase target that regulates cellular proliferation. *Molecular and Cellular Biology* 19:4121-4133.
- Sgouras DN, Athanasiou MA, Beal GJ, Fisher RJ, Blair DG, Mavrothalassitis GJ. (1995) ERF - an ETS domain protein with strong transcriptional repressor activity, can suppress ets-associated tumorigenesis and is regulated by phosphorylation during cell-cycle and mitogenic stimulation. *Embo Journal* 14:4781-4793.
- Sgouras DNE, Duncan R. (1994) Evaluation Of Poly(Glutamic Acid, Alanine, Tyrosine) (1-1-1) As A Lung-Specific Drug-Delivery System .1. Biocompatibility And Studies On Biodistribution In The Rat. *Stp Pharma Sciences* 4:87-94.

- Duncan R, Ferruti P, Sgouras D, Tuboku-Metzger A, Ranucci E, Bignotti F. (1994) A polymer-Triton X-100 conjugate capable of PH-dependent red blood cell lysis: A model system illustrating the possibility of drug delivery within acidic intracellular compartments. *Journal of Drug Targeting* 2:341-347.
- Ranucci E, Spagnoli G, Ferruti P, Sgouras D, Duncan R. (1991) Poly(amidoamine)s with potential as drug carriers: degradation and cellular toxicity. *Journal of Biomaterials Science - Polymer Edition* 2:303-15.
- Sgouras D, Duncan R. (1990) Methods For The Evaluation Of Biocompatibility Of Soluble Synthetic-Polymers Which Have Potential For Bio-Medical Use .1. Use Of The Tetrazolium-Based Colorimetric Assay (MTT) As A Preliminary Screen For Evaluation Of In vitro Cytotoxicity. *Journal of Materials Science-Materials in Medicine* 1:61-68.
- McCormick-Thomson LA, Sgouras D, Duncan R. (1989) Poly(amino acid) copolymers as a potential soluble drug delivery system. 2. Body distribution and preliminary biocompatibility testing in vitro and in vivo. *Journal of Bioactive and Compatible Polymers* 4:252-268.

Book Chapters

- [D. Sgouras, E. Panayotopoulou, K. Papadakos, B. Martinez-Gonzalez, A. Mentis “The contribution of CagA protein in *H. pylori* pathogenesis in the gastric epithelium” 2013, pages 90-108 in “In memoria of Professor Athanassios Archimandritis” Edited by Emer. Prof. M. Tzivras, published by TECHNOGRAMMA (Athens, Greece) 2013] – In Greek
- Sgouras D. and A. Mentis Title: Interaction mechanisms between probiotics and *Helicobacter pylori*. 2005, pg 150-163, in “Probiotics, Biotherapeutics and Health” Edited by C. Schiavi, Published by MOFIN ALCE (Novara, Italy) 2005.

Patents

- Title: ETS2 repressor factor (ERF). Patent Number(s): US 6194547. Assignee: The United States of America as represented by the Department of Health and Human Services. Inventor(s): Mavrothalassitis, George J.; Blair, Donald G.; Fisher, Robert J.; Beal, Gregory J.; Athanasiou, Meropi A.; Sgouras, Dionyssios N.
- Title: ETS2 repressor factor (ERF) genetic locus and its products. Patent Number(s): US 5856125. Assignee: The government of the United States of America as represented by the secretary of the Department of Health and Human Services. Inventor(s): Mavrothalassitis G, M Athanasiou, G Beal, R Fischer, D Blair and D Sgouras

Journal Invited reviewer

Advances in Medical Sciences, American Journal of Gastroenterology, Annals of Gastroenterology, Applied and Environmental Microbiology, BioMed Research International, BMC Clinical Pathology, Digestive Diseases & Sciences, Emerging Infectious Diseases, FEMS Immunology Medical Microbiology, Gastroenterology Research and Practice, Helicobacter, Infection & Immunity, Intervirology, Journal of Medical Microbiology, Microbial Cell Factories, Microbial Drug Resistance, Microbiology, Pharmaceuticals, PLoS ONE, Scandinavian Journal of Gastroenterology, Scientific Reports, Toxins, Yensei Medical Journal.

Teaching Experience

- “*Helicobacter pylori* and human symbiosis: Coevolution and gastric pathogenesis” in the post-graduate teaching program “Microbial Biotechnology” of the Dept. of Biology, Kapodistrian Univ. of Athens for the years 2015-18
- “Physiology of the Gastrointestinal System” in the post-graduate teaching program “Human Biochemistry” of the Dept. of Chemistry, Kapodistrian Univ. of Athens for the years 2011-15
- “Introduction to Human Microbiome” in the post-graduate teaching program “Biological applications in Medicine” of the Dept. of Biology, Kapodistrian Univ. of Athens for the years 2014-18
- Member of the 3- and 7-member evaluation committee in the PhD degrees of Effrossini Panayotopoulou (2013), Konstantinos Papadakos (2015), Ioanna Sougleri (pending 2018), Alexandros Karvelas (pending), Ioannis Karayiannis (pending), Eleftherios Kontizas (pending).
- Member of the 7-member evaluation committee in the PhD degree of Sotirios Paraschos (2010)
- Member of the 3-member committee in the MSc degrees of Ioanna Sougleri (2013), Elissavet Kotsi (2014), Ioannis Karayiannis (2017), Eleftherios Kontizas (2017)
- Responsible scientist for the final year dissertations of Christina Raftopoulou (2006), Aikaterini Loi (2012), Konstantinos Papadakos (2006), Aikaterini Konstantoulaki (2013)

Selected Abstracts in International conferences

- Martinez-Gonzalez, B. *et al. Helicobacter* **22**, (Sept 2017).
- Karayiannis, Y. *et al. Helicobacter* **22** (Sept 2017).
- S.D. Georgopoulos *et al., Helicobacter* **21**, 140 (Sept 2016)
- I. Sougleri *et al., Helicobacter* **20**, 76 (Sept 2015)
- B. Martinez-Gonzalez *et al., Helicobacter*, **20**, 100 (Sept 2015)
- B. Martinez-Gonzalez *et al., Helicobacter*, **20**, 103 (Sept 2015)
- R. M. Ferreira *et al., Helicobacter*, **20**, 105 (Sept 2015)
- K. Papadakos *et al., Helicobacter*, **20**, 120 (Sept 2015)

- S. Georgopoulos *et al.*, *Gastroenterology*, **148**, 422 (May 2015)
M. Boziki *et al.*, *Multiple Sclerosis Journal*, **20**, 247 (Sept 2014)
S.D. Georgopoulos *et al.*, *Helicobacter*, **19**, 80 (Sept 2014)
B. Martinez-Gonzalez *et al.*, *Helicobacter*, **19**, 148 (Sept 2014)
B. Martinez-Gonzalez *et al.*, *Helicobacter*, **19**, 148-149 (Sept 2014)
I. Sougleri *et al.*, *FEBS J*, **281**, 731 (Sept 2014)
S. D. Georgopoulos *et al.*, *Gastroenterology*, **146**, 397 (May 2014)
S. Michopoulos *et al.*, *Gastroenterology*, **146**, 398 (May 2014)
I.S. Sougleri *et al.*, *Helicobacter* **18**, 80 (Sept 2013)
B. Martinez-Gonzalez *et al.*, *Helicobacter*, **18**, 140 (Sept 2013)
K. Papadakos *et al.*, *Helicobacter* **17**, 82 (Sep, 2012)
K. Papadakos *et al.*, *Helicobacter* **16**, 100 (Sep, 2011).
B. Martinez-Gonzalez *et al.*, *Helicobacter* **16**, 118 (Sep, 2011).
S. D. Georgopoulos *et al.*, *Helicobacter* **16**, 134 (Sep, 2011).
E. G. Panayotopoulou *et al.*, *Helicobacter* **15**, 319 (Aug, 2010).
E. Altman *et al.*, *Helicobacter* **15**, 368 (Aug, 2010).
E. Panayotopoulou *et al.*, *Helicobacter* **14**, 373 (Aug, 2009).
K. Papadakos *et al.*, *Helicobacter* **13**, 422 (Oct, 2008).
E. G. Panayotopoulou *et al.*, *Helicobacter* **13**, 411 (Oct, 2008).
E. Panayotopoulou *et al.*, *FEBS J* **275**, 274 (Jun, 2008).
D. N. Sgouras *et al.*, *Helicobacter* **12**, 431 (Aug, 2007).
D. N. Sgouras *et al.*, *Zoonoses and Public Health* **54**, 108 (2007).
B. Martinez-Gonzalez *et al.*, *Helicobacter* **12**, 450 (Aug, 2007).
E. G. Panayotopoulou *et al.*, *Helicobacter* **11**, 334 (Aug, 2006).
D. N. Sgouras *et al.*, *Helicobacter* **10**, 491 (Oct, 2005).
L. De Vuyst *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 232; 87 (2004)
E.G. Panayotopoulou, *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 232; 87 (2004)
L. Makras, *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 232; 77 (2004)
D. Sgouras, *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 232; 93 (2004)
L. De Vuyst, *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 226; 24-25 (2004)
D. Sgouras, *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 60. (2002)
P.A. Maragoudakis, *et al.*, *VTT Symposium (Valtion Teknillinen Tutkimuskeskus)*: 51. (2002)
D. N. Sgouras *et al.*, *Gut* **51**, A18 (Sep, 2002).
S. Michopoulos *et al.*, *Gut* **51**, A60 (Sep, 2002).
Y. Kafritsa *et al.*, *Gut* **51**, A32 (Sep, 2002).
D. N. Sgouras *et al.*, *Gut* **49**, A49 (Sep, 2001).
S. Michopoulos *et al.*, *Gut* **49**, A41 (Sep, 2001).
R. Schoos *et al.*, *Cytogenetics and Cell Genetics* **77**, P185 (1997)